Citations

Clear

1053 citation(s) found for "Andre, F".

An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists
Donskov, Agnete Overgaard , Mackie, Sarah , Hauge, Ellen‐Margrethe , Gutiérrez, Carlos Enrique Toro , Hansen, Ib Tønder , Hemmig, Andrea Katharina , Maas, Aatke van der , Gheita, Tamer A. , Nielsen, Berit Dalsgaard , Douglas, Karen, Matteson, Eric L. , Matza, Mark , Ocampo, Vanessa , Grainger, Rebecca , Bran, Andrea, Appenzeller, Simone , Goecke, Annelise, Colmán, Nelly , Keen, Helen , Kuwana, Masataka , Gupta, Latika, Salim, Babur , Harifi, Ghita , Erraoui, M. , Ziadé, Nelly , Al-Ani, Nizar Abdulateef, Ajibade, Adeola , Frølund, Line L. , Yates, Max , Pimentel-Quiroz, Víctor R. , Lyrio, André Marun , Sandovici, Maria , Geest, Kornelis S. M. van der , Brouwer, Elisabeth , Dejaco, Christian , Keller, Kresten Krarup , Gupta, Latika , Mackie, Sarah Louise , Gheita, Tamer , Conway, Richard , Monti, Sara , Sattui, Sebastian E , Grainger, Rebecca , Keen, Helen , Kuwana, Masataka , Gupta, Latika , Ziade, Nelly , Knitza, Johannes , Pimentel-Quiroz, Victor R , Van der Geest, Kornelis S M , Dejaco, Christian , Keller, Kresten Krarup , Yates, Max , Conway, Richard , Rezuş, Elena , Dasgupta, Bhaskar , Monti, Sara , Sattui, Sebastian E. , Gromova, Margarita Aleksandrovna , Helliwell, Toby

Mayo Clinic

Rheumatology | January 12, 2023 | Volume: 62 | Issue: 8 | Pages: 2797-2805

10.1093/rheumatology/keac713 | PMID 36637182 Get It

Abstract Objectives To explore current management practices for PMR by general practitioners (GPs) and rheumatologists including implications for clinical trial recruitment. Methods An English language questionnaire was constructed by a working group of rheumatologists and GPs from six countries. The questionnaire focused on: 1: Respondent characteristics; 2: Referral practices; 3: Treatment with glucocorticoids; 4: Diagnostics; 5: Comorbidities; and 6: Barriers to research. The questionnaire was distributed to rheumatologists and GPs worldwide via members of the International PMR/Giant Cell Arteritis Study Group. Results In total, 394 GPs and 937 rheumatologists responded to the survey. GPs referred a median of 25% of their suspected PMR patients for diagnosis and 50% of these were returned to their GP for management. In general, 39% of rheumatologists evaluated patients with suspected PMR >2 weeks after referral, and a median of 50% of patients had started prednisolone before rheumatologist evaluation. Direct comparison of initial treatment showed that the percentage prescribing >25 mg prednisolone daily for patients was 30% for GPs and 12% for rheumatologists. Diagnostic imaging was rarely used. More than half (56%) of rheumatologists experienced difficulties recruiting people with PMR to clinical trials. Conclusion This large international survey indicates that a large proportion of people with PMR are not referred for diagnosis, and that the proportion of treatment-naive patients declined with increasing time from referral to assessment. Strategies are needed to change referral and management of people with PMR, to improve clinical practice and facilitate recruitment to clinical trials.
Graduate training in T cell immunotherapy and CAR-T cell therapy
Sterner, Rosalie M. , Hayden, Richard E. , Nowakowski, Grzegorz S. , Wyles, Saranya P. , Greenberg, Alexandra J. , Hedin, Karen E. , Terzic, André , Kenderian, Saad S.

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 204 | Issue: 1_Supplement | Pages: 222.4-222.4

10.4049/jimmunol.204.supp.222.4 Get It

Abstract The objective was to evaluate the impact of an interdisciplinary graduate level course on students’ knowledge and interests in immunotherapy and CAR-T cell therapy. It was a one week course conducted in November 2018. Students were surveyed before and after the course. The survey included questions regarding background, self-perceived knowledge/confidence in skills, and interests/predicted behaviors. Students were assigned to work in interdisciplinary teams to develop a research proposal. A total of 25 students taking the course for graduate level credit were surveyed. Of these, all 25 (100%) completed the surveys. Students came from variable backgrounds and were at different stages of graduate training. After completion of the course, there was a statistically significant increase in self-perceived knowledge of immunotherapy (mean±standard deviation score of 3.6±0.9 post-course vs 2.6±1.0 pre-course, on a 5 point Likert scale, P<0.001), knowledge of the benchtop research to clinic translational process (3.7±0.8 post-course vs 3.0±0.9 pre-course, P<0.001), confidence in critical reading skills (4.3±0.6 post-course vs 4.0±0.5 pre-course, P=0.008), confidence in immunotherapy focused grant writing skills (3.6±0.9 post-course vs 2.8±1.1 pre-course, P<0.001), interest in working in interdisciplinary teams (4.8±0.4 post-course vs 4.6±0.6 pre-course, P=0.02), and interest in attending immunotherapy educational events (3.5±1.3 post-course vs 3.2±1.3 pre-course, P≤0.05). In conclusion, this course helps trainees to build knowledge and interest in the fields of immunotherapy and CAR-T cell therapy and can potentially serve as a platform for future educational courses in interdisciplinary, translational research.
SAHA prevents osteoblast-mediated protection of AML cells via upregulation of Nherf-1 (TUM10P.1050)
Hedin, Karen E. , Kremer, Kimberly N. , Wijnen, André J. van , Westendorf, Jennifer J.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 194 | Issue: 1_Supplement | Pages: 211.31-211.31

10.4049/jimmunol.194.supp.211.31 Get It

Abstract Osteoblasts are known to protect acute myeloid leukemia (AML) cells in the bone marrow microenvironment, however, the identity of these protective signals is not known. Because disrupting this protection could help prevent the relapse of AML patients following chemotherapy, we characterized the molecular mechanisms. We previously showed that SDF-1 (CXCL12), a chemokine abundant in the bone marrow, induces apoptosis of AML cells in cocultures unless the leukemic cells are protected via proximity to differentiating osteoblasts. Treating differentiating osteoblasts with either suberoylanilide hydroxamic acid (SAHA) or LBH-589 histone deacetylase (HDAC) inhibitor drugs inhibited their protection of AML cells. RNAseq revealed that SAHA globally inhibits osteoblast differentiation while inducing expression of the scaffold protein, Nherf-1. Remarkably, expressing Nherf-1 in differentiating osteoblasts was both required and sufficient to block osteoblast-mediated protection of AML cells. Together, these results indicate that disrupting the differentiation of osteoprogenitors in the bone marrow inhibits their ability to protect AML cells from apoptosis, and that this can be achieved via either inhibiting HDACs or overexpressing Nherf-1 in osteoblast-lineage cells. HDAC inhibitors or treatments specifically designed to induce Nherf-1 expression either during or immediately prior to chemotherapy may therefore be a useful strategy for reducing the risk of disease relapse in AML patients.
Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
Carreras‐Torres, Robert , Kim, Andre E. , Lin, Yi , Díez‐Obrero, Virginia , Bien, Stephanie A. , Qu, Conghui , Dimou, Niki , Aglago, Elom K. , Albanes, Demetrius , Baurley, James W. , Berndt, Sonja I. , Bishop, D. Timothy , Bouras, Emmanouil , Brenner, Hermann , Casey, Graham , Chang‐Claude, Jenny , Drew, David A. , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Gsur, Andrea , Harrison, Tabitha A. , Hoffmeister, Michael , Huyghe, Jeroen R. , Jordahl, Kristina M. , Kundaje, Anshul , Li, Li , Nan, Hongmei , Nassir, Rami , Obón‐Santacana, Mireia , Ose, Jennifer , Pai, Rish K. , Papadimitriou, Nikos , Scacheri, Peter C. , Schmit, Stephanie L. , Slattery, Martha L. , Thomas, Duncan C. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Visvanathan, Kala , Vodička, Pavel , Weinstein, Stephanie J. , White, Emily , Woods, Michael O. , Peters, Ulrike , Gauderman, W. James , Wang, Jun , Dimou, Niki , Aglago, Elom K , Albanes, Demetrius , Arndt, Volker , Baurley, James W , Berndt, Sonja I , Bézieau, Stéphane , Bishop, D Timothy , Bouras, Emmanouil , Brenner, Hermann , Budiarto, Arif , Campbell, Peter T , Casey, Graham , Chan, Andrew T , Chang-Claude, Jenny , Chen, Xuechen , Conti, David V , Dampier, Christopher H , Devall, Matthew A M , Drew, David A , Figueiredo, Jane C , Gallinger, Steven , Giles, Graham G , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Harrison, Tabitha A , Hidaka, Akihisa , Hoffmeister, Michael , Huyghe, Jeroen R , Jenkins, Mark A , Jordahl, Kristina M , Kawaguchi, Eric , Keku, Temitope O , Kundaje, Anshul , Marchand, Loïc Le , Lewinger, Juan Pablo , Li, Li , Mahesworo, Bharuno , Morrison, John L , Murphy, Neil , Nan, Hongmei , Nassir, Rami , Newcomb, Polly A. , Obón-Santacana, Mireia , Ogino, Shuji , Ose, Jennifer , Pai, R K , Palmer, Julie R , Papadimitriou, Nikos , Pardamean, Bens , Peoples, Anita R , Pharoah, Paul D P , Platz, Elizabeth A. , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C , Scacheri, Peter C , Schmit, Stephanie L , Schoen, Robert E , Shcherbina, Anna , Slattery, Martha L , Stern, Mariana Carla , Su, Yu-Ru , Tangen, Catherine M , Thomas, Duncan C , Tian, Yu , Tsilidis, Konstantinos K , Ulrich, Cornelia M , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Visvanathan, Kala , Vodicka, Pavel , Cenggoro, Tjeng Wawan , Weinstein, Stephanie J , White, Emily , Wolk, Alicja , Woods, Michael O , Hsu, Li , Peters, Ulrike , Moreno, Victor , Gauderman, W James , Bien, Stephanie A , Carreras-Torres, Robert , Diez-Obrero, Virginia , Qu, Conghui , Arndt, Volker , Bezieau, Stéphane , Campbell, Peter T. , Chan, Andrew T. , Conti, David V. , Dampier, Christopher H. , Giles, Graham G. , Gunter, Marc J. , Hidaka, Akihisa , Jenkins, Mark A. , Marchand, Loı̈c Le , Lewinger, Juan Pablo , Morrison, John L. , Murphy, Neil , Palmer, Julie R. , Pardamean, Bens , Pharoah, Paul D.P. , Rennert, Gad , Sakoda, Lori C. , Schoen, Robert E. , Shcherbina, Anna , Tangen, Catherine M. , Tian, Yu , Tsilidis, Konstantinos K. , Ulrich, Cornelia M. , Wolk, Alicja , Moreno, Vı́ctor

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 28, 2022 | Volume: 32 | Issue: 3 | Pages: 315-328

10.1158/1055-9965.epi-22-0763 | PMID 36576985 Get It

Abstract Background: Tobacco smoking is an established risk factor for colorectal cancer. However, genetically defined population subgroups may have increased susceptibility to smoking-related effects on colorectal cancer. Methods: A genome-wide interaction scan was performed including 33,756 colorectal cancer cases and 44,346 controls from three genetic consortia. Results: Evidence of an interaction was observed between smoking status (ever vs. never smokers) and a locus on 3p12.1 (rs9880919, P = 4.58 × 10−8), with higher associated risk in subjects carrying the GG genotype [OR, 1.25; 95% confidence interval (CI), 1.20–1.30] compared with the other genotypes (OR <1.17 for GA and AA). Among ever smokers, we observed interactions between smoking intensity (increase in 10 cigarettes smoked per day) and two loci on 6p21.33 (rs4151657, P = 1.72 × 10−8) and 8q24.23 (rs7005722, P = 2.88 × 10−8). Subjects carrying the rs4151657 TT genotype showed higher risk (OR, 1.12; 95% CI, 1.09–1.16) compared with the other genotypes (OR <1.06 for TC and CC). Similarly, higher risk was observed among subjects carrying the rs7005722 AA genotype (OR, 1.17; 95% CI, 1.07–1.28) compared with the other genotypes (OR <1.13 for AC and CC). Functional annotation revealed that SNPs in 3p12.1 and 6p21.33 loci were located in regulatory regions, and were associated with expression levels of nearby genes. Genetic models predicting gene expression revealed that smoking parameters were associated with lower colorectal cancer risk with higher expression levels of CADM2 (3p12.1) and ATF6B (6p21.33). Conclusions: Our study identified novel genetic loci that may modulate the risk for colorectal cancer of smoking status and intensity, linked to tumor suppression and immune response. Impact: These findings can guide potential prevention treatments.
Zika virus alters osteogenic lineage progression of human mesenchymal stromal cells
Mumtaz, Noreen , Dudakovic, Amel , Nair, Asha, Koedam, Marijke, Leeuwen, Johannes P.T.M. van , Rockx, Barry , Wijnen, André J. van , Eerden, Bram C. J. van der , Rockx, Barry , van der Eerden, Bram C J , van Wijnen, Andre J , Koopmans, Marion

Mayo Clinic

Journal of Cellular Physiology | December 20, 2022 | Volume: 238 | Issue: 2 | Pages: 379-392

10.1002/jcp.30933 | PMID 36538650 Get It

AbstractArboviruses target bone forming osteoblasts and perturb bone remodeling via paracrine factors. We previously reported that Zika virus (ZIKV) infection of early‐stage human mesenchymal stromal cells (MSCs) inhibited the osteogenic lineage commitment of MSCs. To understand the physiological interplay between bone development and ZIKV pathogenesis, we employed a primary in vitro model to examine the biological responses of MSCs to ZIKV infection at different stages of osteogenesis. Precommitted MSCs were infected at the late stage of osteogenic stimulation (Day 7) with ZIKV (multiplicity of infection of 5). We observe that MSCs infected at the late stage of differentiation are highly susceptible to ZIKV infection similar to previous observations with early stage infected MSCs (Day 0). However, in contrast to ZIKV infection at the early stage of differentiation, infection at a later stage significantly elevates the key osteogenic markers and calcium content. Comparative RNA sequencing (RNA‐seq) of early and late stage infected MSCs reveals that ZIKV infection alters the mRNA transcriptome during osteogenic induction of MSCs (1251 genes). ZIKV infection provokes a robust antiviral response at both stages of osteogenic differentiation as reflected by the upregulation of interferon responsive genes (n > 140). ZIKV infection enhances the expression of immune‐related genes in early stage MSCs while increasing cell cycle genes in late stage MSCs. Remarkably, ZIKA infection in early stage MSCs also activates lipid metabolism‐related pathways. In conclusion, ZIKV infection has differentiation stage‐dependent effects on MSCs and this mechanistic understanding may permit the development of new therapeutic or preventative measures for bone‐related effects of ZIKV infection.
3: PHASE 2 STUDY INTERIM RESULTS OF RBT-1 EFFECT ON POSTOPERATIVE COURSE IN ELECTIVE CABG/VALVE SURGERY
Brown, Craig , Mack, Charles A. , Jessen, Michael E. , Marzouk, Mohamed , Washburn, T Benton, Collar, Alonso, Scavo, Vincent, Bennetts, Jayme , Zager, Richard A. , Lavin, Philip T. , Ruiz, Stacey, Lamy, Andre L. , Assi, Roland , Arghami, Arman , Smith, Julian Anderson , Savage, David, Wang, Chao , Singh, Bhupinder Pal

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 2-2

10.1097/01.ccm.0000905888.62846.0d Get It

Reduce, Reuse, Recycle: Top 10 Choosing Wisely Canada’s Recommendations for Conserving Laboratory Resources
Beriault, Daniel R. , Rodríguez-Capote, Karina , Kinniburgh, David W. , Langman, Loralie J., Mattman, André , Konforte, Danijela , Olechuk, Curtis, Beach, Lori , Leung, Felix , Arnoldo, Saranya , Knauer, Michael , Kalra, Jay , Bouhtiauy, Ihssan, Hassan, Mohamed Abou El, Bailey, Dana , Catomeris, Peter, Simons, Janet , Knauer, Michael J. , Beriault, Daniel R , Knauer, Michael , Hauff, Kristin D. , Chen, Yu , Elnenaei, Manal O.

Mayo Clinic

Canadian Journal of General Internal Medicine | December 5, 2022 | Volume: 17 | Issue: 4 | Pages: 86-95

10.22374/cjgim.v17i4.650 Get It

The COVID-19 pandemic has significantly impacted the production, distribution, and demand of essential laboratory supplies worldwide. In 2021, severe shortages in required laboratory supplies such as blood collection tubes, butterfly needles, and blood gas syringes became a critical issue across Canada. Many hospitals or institutions had to instruct physicians and patients to limit laboratory testing where possible and, in some cases, required emergency shipments of tubes from alternative vendors or nearby hospitals. Laboratory testing is ubiquitous in managing patients. It is used for screening, diagnosis, and monitoring purposes. With limited blood collection tubes, consideration for restricting non-urgent testing is needed to conserve supply and protect acute care departments that manage critically ill patients. In addition, laboratories across Canada have experienced significant staffing shortages, resulting in an even greater need for appropriate laboratory utilization. Consequently, the Canadian Society of Clinical Chemists (CSCC) and the Canadian Association of Medical Biochemists (CAMB) curated utilization recommendations for both hospital and primary care settings in collaboration with Choosing Wisely Canada (CWC). These recommendations were specifically selected from those previously published by Choosing Wisely Canada (CWC), with impact statements and rationales added to conserve at-risk laboratory resources. Supply chain disruptions of clinical laboratory resources are expected to continue throughout 2022, indicating that now, more than ever, a focus on appropriate laboratory utilization is essential.
Abstract 364: Vascular Endothelial Growth Receptor 2 (Flk1) Donor Exosomes Drive Angiogenesis
Rizzo, Skylar A. , Mahlberg, Ryan , Amontree, Ashley, Peterson, Timothy E., Bagwell, Monique, Arrell, D. Kent , Witt, Tyra A. , Nagel, Mary, Park, Sungjo , Sabbah, Michael S. , Li, Mark , Kargaran, Parisa K, Wu, Yue , Li, Jialun , Moran, Steven L. , Shi, Ao , Bagwell, Monique S , Nagel, Mary, Kim, Yohan , Lucien, Fabrice , Terzic, André , Behfar, Atta

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | November 30, 2022 | Volume: 42 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.42.suppl_1.364 Get It

Objectives: Peripheral arterial disease is a significant cause of morbidity and mortality. The goal of this study was to develop a novel treatment to promote angiogenesis. Platelets have been previously implicated in angiogenic events; however, platelet activation rather than presence of growth factors has been associated with new blood vessel formation. This study evaluated exosomes purified from activated platelets to determine their potential in promoting angiogenesis both in vitro and in vivo. Methods & Results: Under Current Good Manufacturing Practices, conditioned medium processed from apheresis platelet cultures yielded a purified exosome product (PEP) enriched for CD63, CD9 and Alix. In vitro, PEP drove HUVEC proliferation, migration, and vascular tube formation. Proteomic evaluation showed Flk1 (VEGFR2) was one of the key angiogenic proteins in PEP. HUVECs treated with Flk1 antibody neutralized PEP (anti-Flk1-PEP) showed reduced vascular tube formation compared to PEP. To evaluate in vivo angiogenesis, a rodent model of hindlimb ischemia was treated with sustained release PEP embedded in fibrin glue (PEP/TISSEEL) with blood flow evaluated by SPY angiography at 28 days post-treatment. Animals treated with PEP/TISSEEL showed improved blood flow with significant difference (p<0.001) as compared to sham, TISSEEL, and anti-Flk1-PEP/TISSEEL. Muscle tissue stained with α smooth muscle actin showed a significant increase (p<0.001) in vascular area in PEP/TISSEEL treated animals compared to TISSEEL alone. To further evaluate clinical translatability, a rabbit ear ischemia wound model was then treated with PEP/TISSEEL. Rabbit ears showed accelerated wound healing and restored blood flow on SPY angiography. Histologic evaluation of vascular area showed a significant increase in vascular area (p<0.05) compared to sham and TISSEEL alone animals. Conclusions: Exosome driven donation of Flk1 here promoted angiogenic events and was successfully translated into healing outcomes in the setting of two animal models of peripheral ischemia. This novel insight into biotherapy achievable pro-angiogenesis establishes a clinical-grade off-the-shelf exosome technology for the treatment of peripheral vascular disease.
Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Oluwole, Olalekan O. , Forcade, Édouard , Muñoz, Javier, Guibert, Sophie de , Lin, Yi , Deol, Abhinav , McSweeney, Peter A., Kersten, Marie José , Jacobson, Caron A. , Thiéblemont, Catherine , Timmerman, John M. , Stiff, Patrick J. , Tzachanis, Dimitrios , Zheng, Yan , Vardhanabhuti, Saran , Shen, Rhine R. , Miao, Harry , Kim, Jenny , Oluwole, Olalekan O , Vose, Julie M. , Bartlett, Nancy L. , Goy, Andre Henri , Farooq, Umar , Minnema, Monique C , Avivi, Irit , Nater, Jenny , Meerten, Tom van

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10399-10401

10.1182/blood-2022-156117 Get It